This element represents the carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development costs, that are statutory in nature, which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

No definition available.

Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details) $ in Thousands, ¥ in Millions	1 Months Ended					3 Months Ended								6 Months Ended	12 Months Ended
	Apr. 30, 2024 USD ($)	Apr. 30, 2024 JPY (¥)	Apr. 30, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 JPY (¥)	Dec. 31, 2024 USD ($) item	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) item	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 28, 2023 USD ($)	Mar. 31, 2022 JPY (¥)	Nov. 30, 2021 USD ($)
Collaboration, License, Promotion and Other Commercial Agreements
Revenue						$ 90,545	$ 91,592	$ 94,396	$ 74,877	$ 117,553	$ 113,739	$ 107,382	$ 104,061		$ 351,410	$ 442,735	$ 410,596
Deferred revenue, current						2,032				2,620				$ 2,620	2,032	2,620
Research and development expense															111,421	116,085	44,265
Accrued research and development costs						6,681				$ 21,331				21,331	6,681	21,331
Collaborative arrangements revenue
Collaboration, License, Promotion and Other Commercial Agreements
Revenue															351,410	442,735	410,596
COUR Pharmaceuticals Development Company, Inc.
Collaboration, License, Promotion and Other Commercial Agreements
Collaborative arrangement, upfront payment			$ 6,000
Collaborative arrangement, option to acquire license, exercise price, payable																				$ 35,000
Research and development expense												$ 6,000
Collaborative arrangement, right to apply credit against future amounts due			$ 6,600
Asahi Kasei Pharma Corporation
Collaboration, License, Promotion and Other Commercial Agreements
Deferred revenue, current						2,000									2,000
Deferred revenue, noncurrent						$ 1,800									$ 1,800
Deferred revenue																		$ 4,300
Collaborative arrangement, upfront payment received				$ 24,600	¥ 3,000
Collaborative arrangement, development related payment, eligible to receive				13,100															¥ 1,600
Collaborative arrangement, development related payment, received				9,000	1,100
Collaborative arrangement, development milestones, eligible to receive				8,200															1,000
Collaborative arrangement, development milestones, received	$ 4,100	¥ 500		4,100	¥ 500
Collaborative arrangement, commercial and sales-based milestone payments, eligible to receive				$ 155,800															¥ 19,000
Collaborative arrangement, performance obligations, number \| item						2									2
Asahi Kasei Pharma Corporation \| Collaborative arrangement, co-promotion agreements
Collaboration, License, Promotion and Other Commercial Agreements
Revenue															$ 2,249	$ 2,009
Asahi Kasei Pharma Corporation \| Collaborative arrangement, development and commercialization agreements
Collaboration, License, Promotion and Other Commercial Agreements
Revenue														$ 2,000	$ 2,200
Alnylam \| Royalty
Collaboration, License, Promotion and Other Commercial Agreements
Revenue																	$ 2,194